Sinil Pharmaceutical Co., Ltd. (KOSDAQ: 012790)

Market Cap	75.77B
Revenue (ttm)	91.70B
Net Income (ttm)	15.07B
Shares Out	11.38M
EPS (ttm)	1,303.47
PE Ratio	5.11
Forward PE	n/a
Dividend	170.00 (2.55%)
Ex-Dividend Date	Dec 27, 2023

Volume	53,567
Average Volume	133,701
Open	6,660.00
Previous Close	6,660.00
Day's Range	6,620.00 - 6,740.00
52-Week Range	5,920.00 - 8,430.00
Beta	1.53
RSI	52.14
Earnings Date	Mar 5, 2025

About Sinil Pharmaceutical

Sinil Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in South Korea and internationally. It offers pharmaceutical products for various indications, such as pain reliever, anti-inflammatory, hyperlipidemia, skin disease, and folic acid deficiency; and general/specialty drugs, veterinary drugs, and OEM products for various diseases. The company also provides cosmetics, including skin care products, etc.; health functional products comprising vitamin supplements; and quasi-drugs for yellow dust, bacteria blocking, etc. In ...

• Industry: Pharmaceutical Preparations
• Founded: 1971
• Employees: 287
• Stock Exchange: KOSDAQ
• Ticker Symbol: 012790

Financial Performance

In 2023, Sinil Pharmaceutical's revenue was 89.14 billion, an increase of 11.41% compared to the previous year's 80.01 billion. Earnings were 13.64 billion, an increase of 12.21%.